MaxCyte Inc (MXCT) concluded trading on Wednesday at a closing price of $2.11, with 0.46 million shares of worth about $0.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.70% during that period and on June 18, 2025 the price saw a loss of about -1.86%. Currently the company’s common shares owned by public are about 106.31M shares, out of which, 97.94M shares are available for trading.
Stock saw a price change of -8.26% in past 5 days and over the past one month there was a price change of -7.46%. Year-to-date (YTD), MXCT shares are showing a performance of -49.28% which decreased to -56.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.10 but also hit the highest price of $5.20 during that period. The average intraday trading volume for MaxCyte Inc shares is 880.47K. The stock is currently trading -6.16% below its 20-day simple moving average (SMA20), while that difference is down -13.37% for SMA50 and it goes to -39.46% lower than SMA200.
MaxCyte Inc (NASDAQ: MXCT) currently have 106.31M outstanding shares and institutions hold larger chunk of about 74.60% of that.
The stock has a current market capitalization of $224.33M. It has posted earnings per share of -$0.40 in the same period. It has Quick Ratio of 11.58 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MXCT, volatility over the week remained 2.58% while standing at 4.28% over the month.
Stock’s fiscal year EPS is expected to rise by 8.33% while it is estimated to increase by 3.78% in next year. EPS is likely to grow at an annualized rate of 9.40% for next 5-years, compared to annual growth of -11.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on November 29, 2023 offering a Buy rating for the stock and assigned a target price of $7 to it. On August 24, 2021, William Blair Initiated their recommendations, while on August 24, 2021, Wedbush Initiated their ratings for the stock with a price target of $36. Stock get a Buy rating from Stifel on August 24, 2021.
